Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.33 +1.91%

+$0.03 today

Market cap
$139.83M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.09M

Average 0.07M

IPHA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Innate Pharma S.A.NASDAQ: IPHA

Research & Development · Q4 FY2025 · quarter ended Dec 2025

Research & development grows 0.1% year over year

Q4 FY2025 research & development of €22.93M rose 0.1% year over year. Over 3 fiscal years it compounded at -5.5% a year.

Context

  • Research & development amounted to 1565.1% of revenue in FY2025, up 1153.3 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€22.93M— QoQ
Last fiscal yearDec 2025
€43.62M-16.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.1%——
1 year-16.1%——
3-year CAGR-5.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
43.62M EUR
Year-over-year change
-16.1%
4-year CAGR
-1.9%

Research & Development vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.1% is the 6th highest of 9, against a peer median of -1.4%.
  • Research & development amounts to 1565.1% of revenue for IPHA, versus a peer median of 760.8%.
IPHA Competitors
Research & Development for IPHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M USD+76.4%+63.2%—
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
IPHAInnate Pharma S.A.FY2025€43.62M EUR-16.1%-5.5%1565.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M USD-19.6%+9.2%6022.3%
CGENCompugen Ltd.LTM Mar 2026$23.92M USD-1.0%-9.4%32.9%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$23.84M USD-29.5%+13.5%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$18.8M USD-26.8%-18.0%593.1%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$18.58M USD+33.3%+11.1%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M USD+5.5%-23.1%928.4%
Peer median (excluding IPHA) —-1.4%+0.9%760.8%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.